Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma.
TCGA
endometrial carcinoma
nucleolin
prognostic marker
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
12
2020
accepted:
05
02
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Nucleolin (NCL) is a multifunctional protein with oncogenic properties. NCL expression levels have been linked to the outcomes of various malignancies, but the clinical value of NCL in patients with endometrial carcinoma (EC) remains unclear. Here, the expression of NCL in EC tissues and its associations with patient outcomes were assessed. Data on NCL mRNA expression in EC and adjacent nonneoplastic tissues from The Cancer Genome Atlas (TCGA) were analyzed. In addition, NCL protein expression in 82 endometroid endometrial adenocarcinoma tissues and 15 non-malignant tissues was detected by immunohistochemistry. Elevated NCL expression was markedly correlated with serous endometrial carcinoma (P<0.001), advanced stage (P=0.029), and grade 3 (P<0.001). High NCL levels were associated with poorer overall survival (OS) and disease-free survival (DFS) compared with intermediate or low NCL levels (OS: P=0.001, DFS: P=0.006). The multivariate Cox proportional hazards model showed that NCL expression was an independent poor prognostic factor for DFS (HR=1.282, CI=1.027-1.601, P=0.028). A similar correlation between high expression levels of NCL and unfavorable DFS was found in endometrioid endometrial adenocarcinoma (HR=1.411, CI=1.083-1.840, P=0.011). Positive extra-nuclear NCL expression (HR=3.377, 95% CI=1.029-11.186, P=0.046) and low nuclear NCL expression (HR=0.233, 95% CI=0.068-0.796, P=0.020) were independent prognostic factors for DFS in endometrioid endometrial adenocarcinoma. Heterotopic NCL is a potential prognostic biomarker for EC. Inhibiting the distribution of NCL from the nucleus to the cytoplasm and membrane may be a promising therapeutic strategy to improve outcomes in patients with EC with high NCL expression.
Identifiants
pubmed: 33658856
doi: 10.2147/CMAR.S294035
pii: 294035
pmc: PMC7920503
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1955-1965Informations de copyright
© 2021 Lin et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cancers (Basel). 2018 Oct 22;10(10):
pubmed: 30360377
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Recent Pat Anticancer Drug Discov. 2014 May;9(2):137-52
pubmed: 24251811
Nucleic Acids Res. 2011 Oct;39(19):8513-30
pubmed: 21737422
Commun Integr Biol. 2011 May;4(3):267-75
pubmed: 21980556
Tumour Biol. 2016 Aug;37(8):10349-56
pubmed: 26846099
Blood. 2013 Jun 6;121(23):4729-39
pubmed: 23599269
J Cancer Res Clin Oncol. 2003 Jan;129(1):43-51
pubmed: 12618900
Cancer Res. 2011 May 1;71(9):3296-305
pubmed: 21415166
PLoS One. 2016 Dec 1;11(12):e0167094
pubmed: 27907160
Oncotarget. 2016 Dec 27;7(52):87016-87030
pubmed: 27894092
Mol Ther Nucleic Acids. 2016 Aug 30;5(8):e358
pubmed: 27574784
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361
pubmed: 29045681
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9418-23
pubmed: 26170308
BMC Mol Biol. 2007 Aug 10;8:66
pubmed: 17692122
J Biol Chem. 2004 Mar 19;279(12):10855-63
pubmed: 14679209
Mol Med Rep. 2014 Sep;10(3):1489-94
pubmed: 24927373
Oncotarget. 2015 Dec 8;6(39):42091-104
pubmed: 26540346
Blood. 2007 Apr 1;109(7):3069-75
pubmed: 17179226
Biochimie. 2015 Jun;113:78-85
pubmed: 25866190
PLoS One. 2008 Jun 18;3(6):e2518
pubmed: 18560571
Mol Pharmacol. 2005 Jan;67(1):319-26
pubmed: 15492114
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
PLoS One. 2017 Jan 19;12(1):e0170160
pubmed: 28103300
Mol Cell Biochem. 2016 Jun;417(1-2):141-53
pubmed: 27221739
J Gynecol Oncol. 2019 May;30(3):e46
pubmed: 30887763
PLoS One. 2013;8(1):e54674
pubmed: 23382938
APMIS. 2013 Oct;121(10):919-25
pubmed: 23763304
Curr Top Med Chem. 2014;14(13):1574-89
pubmed: 25159167
Cancer Res. 2016 Dec 15;76(24):7181-7193
pubmed: 27754848
J Biol Chem. 2012 May 11;287(20):16467-76
pubmed: 22433872
Biochimie. 2011 Mar;93(3):426-33
pubmed: 21040752
Cell. 1989 Feb 10;56(3):379-90
pubmed: 2914325
Proc Natl Acad Sci U S A. 1973 May;70(5):1316-20
pubmed: 4351171
Diagn Pathol. 2014 Sep 18;9:175
pubmed: 25230759
Asian Pac J Cancer Prev. 2015;16(8):3301-6
pubmed: 25921135
Tumour Biol. 2015 Feb;36(2):1099-104
pubmed: 25326811
Curr Opin Oncol. 2020 Sep;32(5):471-480
pubmed: 32740093
Epigenomics. 2012 Apr;4(2):147-62
pubmed: 22449187